

Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

<https://marketpublishers.com/r/E6E6F579AEC9EN.html>

Date: September 2025

Pages: 210

Price: US\$ 2,999.00 (Single User License)

ID: E6E6F579AEC9EN

Abstracts

The Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) was valued at in and is anticipated to reach by , at a CAGR of xx% from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031).

This report delivers a comprehensive overview of the Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry,

Forecast and outlook (2024-2031) Scope:

Major Highlights

This report delivers a comprehensive overview of the Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031), with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031). The Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for –.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

Why Choose DataM?

Data-Driven Insights: Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

Post-Purchase Support and Expert Analyst Consultations: As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

White Papers and Case Studies: Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing strategies for maximum impact.

Annual Updates on Purchased Reports: As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

Specialized Focus on Emerging Markets: DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

Value of DataM Reports: Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement

and go beyond what is typically available in generic databases.

Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Contents

ERECTILE DYSFUNCTION THERAPEUTICS PIPELINE ANALYSIS

- Erectile dysfunction therapeutics also called as impotence, is nothing but the inability or a form of sexual dysfunction where a man cannot retain a firm erection of the penis for coitus.
- Erectile dysfunction is more likely to affect people with blood clots, low blood pressure, and heart problems. It can be cured with appropriate medications.
- The predisposing factors are tobacco usage, injuries, overweight, drug and alcohol use. And medications include antidepressants, antihistamines and also include medications to treat high blood pressure, and pain or prostate cancer.
- At present, there are five oral drugs available to treat ED — Sildenafil (Viagra), avanafil (Stendra), vardenafil (Levitra, Staxyn), and tadalafil (Cialis). A number of pharmaceutical companies are investigating new treatments for ED, and many new options may be forthcoming.
- Uprima (apomorphine) that works by stimulating the brain chemical dopamine, which heightens sexual interest and sensations. Currently, clinical trials are also being conducted on a nasal spray form of this drug, which may cause less nausea.
- Topiglan uses the drug (alprostadil) that is injected sold under the brand names Caverject, Edex and Prostin VR—as well as a suppository-form of alprostadil, sold under the name MUSE, are at patients' disposal. Melanocortin activators like the drug (PT-141) that acts through the central nervous system. Gene therapy is a novel therapy that would deliver genes, which will produce products or proteins that may not be operating properly in the penile tissue of men with ED.
- Replacement of the proteins may also result in erectile function improvement. But Gene therapy may take a long time for regulatory approval and for the public acceptance.
- Viagra drugs are dominating in the erectile dysfunction market. Levitra (vardenafil) from Bayer AG and Cialis (tadalafil) from Eli Lilly & Co. are known to be the competitors for Viagra globally and after the patent expiration of these drugs, the other drugs such as Zydenna (udenafil), Stendra/Spedra, and Vitaros (Alprostadil Cream) are expected to capture the market growth during the next five years.
- Oral phosphodiesterase type 5 (PDE-5) inhibitors are commonly used in erectile dysfunction drugs across the globe. Further, Zydenna containing udenafil, a PDE-5 inhibitor is manufactured and sold by Dong-A Pharmaceutical Co. Ltd. is expected to produce increased growth.
- This drug is distinguished from other PDE 5 inhibitors because of its longer duration of action and fewer incidences of side effects including vision disturbances and muscle pain.

- However, it has been found that about 50 drug molecules are currently in clinical trials, among which few drugs are expected to launch owing to increase in erectile dysfunction market proportionally. There are also medical devices like the Elator, which is approved by the Food and Drug Administration (FDA) and it is custom-made based on a patient's girth and shaft with medical-grade silicone.
- Global erectile dysfunction drugs market continues to witness positive growth owing to the increased occurrence of chronic diseases, increase in lifestyle changes among the young population, rising geriatric population with the increase in the prevalence of erectile dysfunction would be expected to fuel demand erectile dysfunction drugs.
- The market of erectile dysfunction drugs steered by increasing generic product launch by local vendors, possible patent expires of erectile dysfunction drugs are anticipated, and promising product pipeline clinical developments are expected to propel the market for erectile dysfunction drugs.
- However, the availability of several counterfeit drugs, side effects associated with the use of erectile dysfunction drugs, a social taboo accomplice with erectile dysfunction in developing economies may hinder the growth of the erectile dysfunction drugs market.

I would like to order

Product name: Erectile Dysfunction Therapeutics – Pipeline Insight – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) 2026

Product link: <https://marketpublishers.com/r/E6E6F579AEC9EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/E6E6F579AEC9EN.html>